Mathieu Pieronne
Director, venture capital life sciences at Andera Partners
Mathieu Pieronne
Director, venture capital life sciences at Andera Partners
Paris, Île-de-France
Overview
Work Experience
Director, venture capital life sciences
2014 - Current
Director: April 2024 - Investment director: April 2021 - April 2024 Investment manager: April 2018 - April 2021 Analyst: April 2015 - April 2018 Intern: May 2014 - April 2015 Deal list: BioVentrix series A (2023), Sonivie series C (2023), Amolyt series B (2021 - acquired by AZ for 1.05Bn$), AM Pharma (2019), HighLife series B (2018), T-Knife seed round (2018), Dynacure series B (2018), Tricares series B (2018), Crescendo Biologics (2018), GamaMabs (2015) Board positions: Sonivie (observer), HighLife (observer), MedLumics (administrator) Scientific, business and financial analysis of worldwide Medtech and Biotech opportunities from prototype/lead optimisation to late clinical development stage for direct investments. • Carried out due-diligence: technological, strategic and intellectual property assessment • Performed scientific analyzes of deal opportunities • Realized Investment Notes for the Investment Committee • Appointed as board observer and invited guest to multiple boards • Worked on multiple reinvestments (convertible loans, internal and external equity rounds) of portfolio companies • Worked with an international team on a daily basis • Participated in reporting to the limited partners
Lecturer
2017 - 2019
Introduction to venture capital to students of the Chair of innovation management & healthcare performance
Intern
2013 - 2013
Dévelopment et optimisation de patchs cardiaques ensemencés avec des progéniteurs cardiaques dérivés de cellules souches embryonnaires humaines pour le traitement de l'insuffisance cardiaque. Participation à l'essai clinique ESCORT. Development and optimisation of cardiac patches seeded with human embryonic stem cell-derived cardiac progenitors for heart regeneration. ESCORT clinical trial phase 1. Publication: Mechanical characterization of new clinically relevant fibrin-based hydrogels for heart repair using shear wave ultrasound elastography Abstract Materials Research Society Meeting Fall 2013 Principal investigator: Pr. Philippe Menasché
Intern
2012 - 2012
Equipe 10. Percutaneous Arterial Repair. Etude des facteurs de remodelage matriciel impliqués dans le développement de l'anévrysme de l'aorte abdominale. Analyse des interactions entre le tissus hôte et le produit de thérapie cellulaire. Study of aortic abdominal aneurysm treatment by gingival cell therapy. Principal investigator: Pr. Antoine Lafont
Intern
2010 - 2010
Etude des facteurs prédisposants au syndrome hémolytique et urémique atypique. Study of predisposing factors to atypical hemolytic uremic syndrome.
Intern
2009 - 2009
Diagnostic pré et post natal. Génétique médicale. Pre-and postnatal diagnosis. Medical genetics.